HELIX BIOPHARMA Market Capitalization vs. Cash Flow From Operations

HBP Stock  EUR 1.15  0.00  0.00%   
Based on the key profitability measurements obtained from HELIX BIOPHARMA's financial statements, HELIX BIOPHARMA may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess HELIX BIOPHARMA's ability to earn profits and add value for shareholders.
For HELIX BIOPHARMA profitability analysis, we use financial ratios and fundamental drivers that measure the ability of HELIX BIOPHARMA to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well HELIX BIOPHARMA utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between HELIX BIOPHARMA's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of HELIX BIOPHARMA over time as well as its relative position and ranking within its peers.
  
Check out Risk vs Return Analysis.
Please note, there is a significant difference between HELIX BIOPHARMA's value and its price as these two are different measures arrived at by different means. Investors typically determine if HELIX BIOPHARMA is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, HELIX BIOPHARMA's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

HELIX BIOPHARMA Cash Flow From Operations vs. Market Capitalization Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining HELIX BIOPHARMA's current stock value. Our valuation model uses many indicators to compare HELIX BIOPHARMA value to that of its competitors to determine the firm's financial worth.
HELIX BIOPHARMA is rated below average in market capitalization category among its peers. It also is rated below average in cash flow from operations category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the HELIX BIOPHARMA's earnings, one of the primary drivers of an investment's value.

HELIX Market Capitalization vs. Competition

HELIX BIOPHARMA is rated below average in market capitalization category among its peers. Market capitalization of Other industry is currently estimated at about 19.54 Trillion. HELIX BIOPHARMA adds roughly 38.94 Million in market capitalization claiming only tiny portion of all equities under Other industry.
Capitalization  Total debt  Valuation  Workforce  Revenue

HELIX Cash Flow From Operations vs. Market Capitalization

Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.

HELIX BIOPHARMA

Market Cap

 = 

Shares Outstanding

X

Share Price

 = 
38.94 M
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.

HELIX BIOPHARMA

Operating Cash Flow

 = 

EBITDA

-

Taxes

 = 
(6.51 M)
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.

HELIX Cash Flow From Operations Comparison

HELIX BIOPHARMA is currently under evaluation in cash flow from operations category among its peers.

HELIX Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on HELIX BIOPHARMA. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of HELIX BIOPHARMA position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the HELIX BIOPHARMA's important profitability drivers and their relationship over time.

Use HELIX BIOPHARMA in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if HELIX BIOPHARMA position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in HELIX BIOPHARMA will appreciate offsetting losses from the drop in the long position's value.

HELIX BIOPHARMA Pair Trading

HELIX BIOPHARMA Pair Trading Analysis

The ability to find closely correlated positions to HELIX BIOPHARMA could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace HELIX BIOPHARMA when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back HELIX BIOPHARMA - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling HELIX BIOPHARMA to buy it.
The correlation of HELIX BIOPHARMA is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as HELIX BIOPHARMA moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if HELIX BIOPHARMA moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for HELIX BIOPHARMA can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your HELIX BIOPHARMA position

In addition to having HELIX BIOPHARMA in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Office Supplies Thematic Idea Now

Office Supplies
Office Supplies Theme
Companies producing and selling office supplies, and accessories. The Office Supplies theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Office Supplies Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for HELIX Stock Analysis

When running HELIX BIOPHARMA's price analysis, check to measure HELIX BIOPHARMA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HELIX BIOPHARMA is operating at the current time. Most of HELIX BIOPHARMA's value examination focuses on studying past and present price action to predict the probability of HELIX BIOPHARMA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HELIX BIOPHARMA's price. Additionally, you may evaluate how the addition of HELIX BIOPHARMA to your portfolios can decrease your overall portfolio volatility.